“Preventive genomics is not yet recommended as standard of care,” Robert Green, director of the Preventive Genomics Clinic, said in a statement. “But for over two decades, our NIH-funded, randomized trials in translational genomics have generated consistent evidence that there are more potential medical benefits and fewer risks than previously considered. It is time for … Continued
News & Media
Use our Project or Categories filter to narrow down your news search.
Brigham and Women’s Hospital has launched the Preventive Genomics Clinic, a facility designed to provide comprehensive DNA sequencing, interpretation and reporting of disease-associated genes.
Researchers led by Robert Green at Brigham and Women’s Hospital looked at whether consumers getting direct-to-consumer genetic testing were using PGx tests to change treatment decisions. Although this study relied on self-reported data from participants, it suggests that less than 1 percent could have made unsupervised medication changes based on their genetic test results.
Brigham and Women’s Hospital on Friday unveiled a new Preventive Genomics Clinic that will offer a menu of options for a genetic workup, with price tags ranging from $250 to $2,950, depending on how many genes are analyzed; it’s the first program of its kind that will offer the sequencing to children in addition to adults.
The preventive genomics clinic is offering what’s arguably the opposite of modestly priced, do-it-yourself tests: It’s a full-service genomics clinic for patients who want the elite care of an academic medical center and will pay for it out of pocket.
Nation’s first academic clinic to offer comprehensive DNA sequencing and genetic risk assessment to healthy adults and children
Disruptive philanthropist, activist and fashion innovator Iman Abdulmajid will receive the award at a dinner on the eve of the 76th Venice Film Festival.
“I would have never known that I was at risk if i hadn’t donated to the Biobank,” said Kristine Trudeau who knowingly enrolled in the Partners HealthCare Biobank because she wanted to help advance medicine and potentially save lives. She did not expect that it would save her own.
The first major randomized clinical trial on the effect of disclosing genetic information found that people who decided to learn about their genetic risk of developing Alzheimer’s disease did not experience large, negative psychological impacts.
More and more people want to explore their own medical data, and a DTC genetic test is one way to begin to understand some aspects of your future health.
At a new clinic in Boston, genetic counselor Carrie Blout helps healthy patients get their DNA tested for predispositions to more than 2500 diseases. Bloomberg’s Aki Ito goes through the testing herself, trialing a controversial technology at the forefront of modern medicine.
Dr. Robert Green and Kreg Klugman explore the pros and cons of knowing one’s risk for developing Alzheimer’s.
Babies are tested for a number of conditions soon after birth, but varied approaches to screening worldwide highlight how fragmented the medical profession remains over this vital process.
MIT scientists used a novel tool to try to edit out a genetic risk for Alzheimer’s disease, they report in the journal Science. Dr. Robert Green gives his opinion on the new technology.
Dr. Robert Green on learning of your genetic risk to developing Alzheimer’s quotes: “Not everything has a pill or medical-prevention plan, but many information-seeking persons can find all sorts of benefits in better understanding their risk of future disease.”
Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?
A decade ago, it seemed inevitable that every newborn would get a complete gene scan. But there are technical challenges and practical concerns.Dr. Robert Green, from Brigham and Women’s Hospital in Boston, voiced one view about doing that: “If sequencing reveals health risks at any point in life, and if that’s good, then it’s better … Continued
Kristine Trudeau agreed to donate a sample of blood to the Partners HealthCare Biobank, a resource for researchers across the Partners hospital network — including the Brigham and Massachusetts General. By analyzing large numbers of blood samples, scientists can learn how genes contribute to disease. Trudeau shares her experiences as being one the many participants … Continued
Robert Green, MD, MPH, of the Division of Genetics, was included in BIS Research and Insight Monk’s Top 25 Voices in Precision Medicine for his work on medical genetics and genomics.
Continuous new discoveries about the genome make updates important.
G2P’s summer began with our team members participating in the Boston Athletic Association 10K on Sunday June 23rd! Over the past few months, G2P faculty have attended numerous conferences nationwide, been featured in podcasts discussing the new preventive genomics clinic, and engaged with leaders in science, business, and industry in support of the Franca Fund.
Under the four-year collaboration, experts in genomic medicine from Harvard and Brigham and Women’s will help guide Sanford researchers in using and interpreting data collected through the Sanford Chip, a $49 pharmacogenomic test to identify genetic risk factors for medication use and more accurately prescribe medications.
The collaboration between Sanford Health and Harvard Medical will help guide best practices for offering genetic testing to patients and improving health outcomes
What would happen if everyone got their genome sequenced? This question is no longer the stuff of science fiction. Instead, it is a research question that Senior Genetic Counselor Carrie Blout and her colleagues at the Genomes2People initiative at Brigham and Women’s hospital are trying to answer. We discuss the medical, psychological, and economic impact … Continued
When a newborn’s genome is sequenced, should some results be withheld?
Nearly 90 percent of participants who carried a BRCA mutation would have been missed by 23andMe’s test, geneticists found. Dr Robert Green comments, “I think people have the right to their own genetic information, but with that right comes a responsibility. If you are going to go around the medical mainstream, read the caveats.”
Dr. Robert Green, Dr. Jason Vassy, and numerous researchers share their thoughts on the Spain-based Patia that is currently offering an assessment that includes a 16-SNP polygenic risk score.
Tala Berro, MS, LCGC writes about her experiences as a minority genetic counselor during her training and clinical rotations. Berro shares, “To my fellow genetic counselors, I propose the following version of the golden rule: treat your peers as you treat your patients”.
Pediatric oncologist Dr. Lisa Diller, the Lillian Gollay Knafel Fellow at the Radcliffe Institute for Advanced Study, is exploring genetic testing in newborns that could help them escape severe health consequences.
Spring saw accomplishments by team members through numerous projects. G2P officially kicked-off the PeopleSeq consortium in Boston this January! Our very own, Carrie Blout, MS, CGC, was one of 86 Partner’s individuals awarded the Partners In Excellence Award.
Parents and clinicians have their own ideas about newborn genome sequencing. Dr. Robert Green, principal investigator of the BabySeq Project, shares a detailed analysis of the results from the study and his thoughts on the utility of genomic sequencing for newborns in clinical care.
Highlighting the changes that are happening within direct to consumer testing, experts predict that consumer genomics will become “the new normal,” with the companies in this space and healthcare providers working together to find the best path forward.
Carrie Blout, MS, CGC, Director of Research Development and Senior genetic Counselor at Genomes2People was selected as a 2019 Individual recipient of the Partners In Excellence Awards- awarded to individuals at Partners HealthCare for going above and beyond in their work efforts.
The PeopleSeq Consortium officially kicked off their NIH- funded project in Boston, bringing together a cohort of leading academic and industry collaborators.
Researchers analyzed nearly 5,000 genes looking for the risk of diseases and found that almost 10 percent of babies tested were at risk for a condition that could be treated early.
As principal investigator on the BabySeq Project, Dr. Robert Green shares the findings from the project along with discussion on the expectations and benefits of sequencing healthy babies. Green states, “Suddenly the information available in the genome of even an apparently healthy individual is looking more robust, and the prospect of preventive genomics is looking … Continued
“The larger goal of the fund is to change the way people think about medicine,”Francesco Carrozzini, son of Franca Sozzani, states. “To make medicine more proactive and accessible. By doing so, we can help prevent millions of deaths and diseases.”
In the BabySeq Study, a total of 88% of sequenced neonates had carrier status for one or more rare genetic variants known to be associated with recessive diseases.
Getting out in front of disease is the ultimate goal of DNA screening like the BabySeq project, says Dr. Robert Green, its joint director and a Harvard Medical School professor.
A trial called BabySeq, in which researchers performed genomic sequencing on 159 newborns, identified children susceptible to diseases that regular screening doesn’t look for.